TScan Therapeutics (TCRX) Total Debt (2022 - 2026)

TScan Therapeutics (TCRX) has 5 years of Total Debt data on file, last reported at $32.7 million in Q1 2026.

• On a quarterly basis, Total Debt rose 1.47% year-over-year to $32.7 million in Q1 2026; TTM through Mar 2026 was $32.7 million, a 1.47% increase from a year earlier, with the FY2025 full-year figure at $32.5 million, up 1.44% from the prior year.
• Total Debt for Q1 2026 stood at $32.7 million, roughly flat from $32.5 million in the prior quarter.
• Over the last five years, Total Debt for TCRX reached as high as $32.7 million in Q1 2026 and fell as low as $29.1 million in Q3 2022.
• Historically, Total Debt has averaged $30.9 million across 5 years, with a median of $30.4 million in 2024.
• Across the five-year window, Total Debt gained 6.74% in 2024 and advanced 1.44% in 2025, its largest moves.
• Year by year, Total Debt stood at $29.3 million in 2022, then advanced by 2.58% to $30.0 million in 2023, then gained by 6.74% to $32.1 million in 2024, then gained by 1.44% to $32.5 million in 2025, then gained by 0.37% to $32.7 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $32.7 million in Q1 2026, $32.5 million in Q4 2025, and $32.4 million in Q3 2025.